Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The receptors for HER2 are overexpressed in various human cancers, such as breast and ovarian cancer.
|
31470531 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of the multicenter study is to investigate the correlation between the expression of estrogen alpha receptors (ERα), progesterone receptors (PR), human epidermal growth factor receptor 2 (HER2), stromal cell-derived factor 1 (SDF1) and its receptor C-X-C chemokine receptor type 4 (CXCR4), breast cancer metastasis suppressor 1 (BRMS1), astrocyte elevated gene 1 (AEG1), depending on the status of BRCA1 protein, in patients suffering from OC and BC with brain metastases.
|
30822630 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of HER2/HER3 and clinical feature of ovarian cancer.
|
31328457 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, HER2 protein is over-expressed in epithelial ovarian cancer tissues, and trastuzumab exerts anti-tumor effect by inhibiting cell proliferation and inducing apoptosis, suggesting it might be a novel approach for the treatment of ovarian cancer.
|
30509111 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
In order to assess the validity of ErbB2-targeted therapy in ovarian cancer, we investigated the effectiveness of two FDA-approved tyrosine kinase inhibitors of ErbB2, lapatinib and neratinib, on the growth of ovarian cancers.
|
31689531 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present work we combined functional and spectroscopic magnetic resonance technologies, such as in vivo diffusion-weighted MRI and <sup>1</sup> H MRS, with ex vivo high resolution MRS (HR-MRS) metabolomic analyses, with the aim of identifying new pharmacodynamic markers of Trab effectiveness on well characterized, highly aggressive human SKOV3.ip (a HER2-enriched cell variant derived from SKOV3 cells) EOC xenografts.
|
30375088 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
HER2 amplifications and overexpression in ovarian cancer are reported to vary, and responses to HER2 inhibitors have been poor.
|
30499260 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, analyses that considered all 41 genes with clinical variables together identified genes TLR4, BSCL2, CDH1, ERBB2, BRCA2 and SCGB2A1 as independently related to survival in OC.
|
31655274 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.
|
31376137 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy.
|
30856589 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
The prognostic role of human epidermal growth factor receptor 2 (HER2) in ovarian cancer has been investigated in previous studies, but the results remain controversial.
|
29381731 |
2018 |
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The data demonstrate that the growth of xenografts of human ovarian cancer with high expression of HER2 could be inhibited effectively by Ad-HER2-siRNA+DDP.
|
30052070 |
2018 |
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
HER2-targeting properties and biodistribution were evaluated in BALB/C <i>nu/nu</i> mice bearing ovarian carcinoma cell (SKOV-3) xenografts.
|
28864631 |
2018 |
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
HER2 is a member of epidermal factor receptor (EGFR) family which is overexpressed in breast cancer, ovarian cancer and gastric cancer.
|
30225583 |
2018 |
Carcinoma, Ovarian Epithelial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic association between HER2 and ESR2 polymorphisms and ovarian cancer: a meta-analysis.
|
29535531 |
2018 |
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Aberrant <i>EGFR</i> expression and <i>ERBB2/3/4</i> mRNA levels were associated with OC prognosis.
|
30588099 |
2018 |
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
CTD_human |
In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer.
|
28811376 |
2017 |
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PET imaging and biodistribution studies in subcutaneous models of ovarian cancer were performed for non-invasive in vivo evaluation of HER2 expression.
|
28265738 |
2017 |
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Neratinib's in vivo efficacy was evaluated in HER2-amplified epithelial ovarian carcinoma xenografts.
|
28397106 |
2017 |
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our study showed that the expressions of HER2, STAT3, and SOCS3 are associated with the progression of OC, and higher expressions of HER2 and STAT3 and lower expression of SOCS3 predict poor prognosis of OC.
|
28448787 |
2017 |
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PubMed and Embase were searched for studies that reported HER-2/neu expression and survival in patients with EOC.
|
29088888 |
2017 |
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Goals of this study were: i) to define a possible association between Estrogen Receptor (ER), Progesterone Receptor (PR), Androgen Receptor (AR),human EGF receptor 2 (HER2) and brain progression in EOC patients, and ii) to identify differences in ER, PR, AR and HER2 protein expression from primary EOC and its matched resected brain metastasis.
|
28467804 |
2017 |
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
SYD985 and T-DM1 induced similar ADCC in the presence of peripheral blood lymphocytes (PBL) against EOC cell lines with differential HER2/neu expression.
|
28473206 |
2017 |
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overall, these findings support the view that PC-PLC inhibition may represent an effective means to target the tumorigenic effects of HER2 overexpression in EOC and that <i>in vivo</i> MR approaches can efficiently monitor its effects.
|
28903399 |
2017 |
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
T, P, T+P, and T-DM1 were similarly effective in inducing strong ADCC against primary EOC cell lines expressing 3+ HER2/neu.
|
28705408 |
2017 |